Articles tagged with Osteoclasts
Researchers have successfully mapped the cells and genes that regulate bone formation and loss, revealing blood vessel cells play a critical role in bone health. The discovery has the potential to enable the development of new therapies to reverse bone loss and improve treatments for osteoporosis and other skeletal conditions.
A new study reveals the developmental mechanism of bone marrow formation, identifying septoclasts as early organizers followed by LepR-expressing bone marrow stromal cells. These specialized cell populations work together to build the bone marrow environment through a hardwired process supported by RANKL.
Brazilian researchers analyzed over 60 scientific articles on microplastics and their impact on bone health. They found that the materials can impair bone marrow stem cells, accelerate cell aging, and promote inflammation, leading to potential bone weakening and fractures.
Scientists at Leipzig University have discovered that the adhesion G protein-coupled receptor GPR133 plays a central role in building and maintaining healthy bone. By mimicking natural activation, a new active substance AP503 can strengthen bones and potentially treat osteoporosis.
Researchers identify Fam102a as a key regulator of both osteoclast and osteoblast differentiation, leading to enhanced osteoblast formation and bone volume. The study reveals significant protein-protein interactions involving Fam102a and Kpna2, shedding light on the critical molecular interactions involved in bone remodeling.
Researchers discover that osteogenic CpG oligodeoxynucleotide iSN40 inhibits osteoclast differentiation and reduces bone resorption. This balanced approach could provide a new treatment option for osteoporosis, an imbalance in bone remodeling characterized by excessive bone resorption.
Researchers are studying the role of stress hormones and mineralocorticoid receptors in bone health as we age. The goal is to understand how balance between these factors affects our skeletons. By investigating this complex relationship, scientists hope to develop new insights into osteoporosis and other age-related bone disorders.
A research team from Osaka University identified a key osteoporosis-related gene, Men1, and developed a new animal model of the disease. The study found that inactivation of Men1 led to cellular senescence in osteoblasts, reducing bone formation activity and increasing bone resorption.
Researchers have identified a novel target downstream of parathyroid hormone signaling that suppresses bone formation. Gprc5a negatively regulates osteoblast proliferation and differentiation by partially suppressing BMP signaling, potentially increasing teriparatide effectiveness in non-responding patients.
Researchers discover novel suppressive role of Ctdnep1 in osteoclast differentiation and bone resorption, suggesting potential therapeutic targets for treating excessive bone loss. The study reveals that Ctdnep1 functions as a brake on osteoclast cell differentiation.
Researchers found that chlorogenic acid enhances osteoblast proliferation and differentiation, while inhibiting RANKL-induced osteoclastogenesis. Administration of chlorogenic acid antagonizes ovariectomized-induced bone loss in rats.
Scientists from Tokyo Medical and Dental University have created Opto-RANK, a light-activated form of RANK that can induce osteoclast differentiation. The treatment approach uses blue light activation to stimulate local bone resorption, making it a promising tool for treating abnormal calcification diseases and orthodontic issues.
Researchers from Tokyo University of Science identify Cpeb4 protein's crucial role in mRNA splicing and osteoclast differentiation, shedding light on bone disease mechanisms. The study's findings may lead to new diagnostic techniques and treatments for conditions like osteoporosis.
Researchers at Rice University have discovered a promising new immunological pathway to treat stubborn bone tumors in breast cancer patients. The glyco-immune checkpoint axis, involving protein Siglec-15, plays a crucial role in hiding bone tumors from the immune system.
Researchers have identified a potential treatment for lower back pain by targeting senescent osteoclasts in the vertebral column of mice. Using anti-senescent drugs like Navitoclax may relieve spinal sensitivity and reduce pain, according to the study published in eLife.
Researchers developed an innovative imaging technique to study cells in bones of mice, revealing distinct pockets of bone resorption activity. This knowledge could lead to new treatments for osteoporosis and dormant cancer cells.
A team of Osaka University researchers discovered a link between Rab32 and Rab38 proteins, crucial for both hair pigmentation and bone resorption. Double-knockout mice showed increased bone density and altered physical characteristics, highlighting the importance of these proteins in maintaining bone homeostasis.
Researchers found that morphine interacts with toll-like receptor 4 to contribute to increased bone loss and pain. Blocking TLR4 prevents these effects, suggesting a new target for reducing opioid side effects.
A new study by Van Andel Institute scientists identifies KDM5C as a key driver of low bone density, preserving bone mass in mice. The discovery may lead to more effective treatments for women with osteoporosis, reducing the risk of fractures and improving quality of life.
Researchers at MUSC found that extracting and isolating Treg cells and transplanting them back into the same system successfully treats osteogenesis imperfecta for a year. The treatment results in stronger bones, increased osteoblast numbers, and decreased osteoclast numbers.
A study found that elevated blood levels of chemokine CXCL9 predict the risk of osteoporotic hip fracture in men. Researchers discovered a significant association between CXCL9 and hip fractures in a cohort of Chinese men, highlighting the potential for early interventions targeting CXCL9 to prevent hip fractures.
Researchers have identified a new protein called IFT80 that regulates osteoclasts, the cells responsible for breaking down bone. The study found that mice lacking IFT80 developed severe osteopenia, highlighting its potential as a therapeutic target for treating bone loss diseases.
Researchers found that CXCL9 levels were higher in pre-fracture blood samples of Chinese men with subsequent hip fractures, improving the prediction of osteoporotic hip fracture risk in men. In contrast, no association was found between CXCL10 and hip fracture risk in either gender.
A recent study found that a subset of immune cells within the alveolar bone marrow were activated by the presence of commensal oral microbes, leading to increased osteoclast-mediated bone resorption and bone loss. Reducing the burden of commensal microbes through oral antiseptic rinses can help protect against alveolar bone loss.
A study by Tokyo University of Science researchers identifies a novel regulatory axis targeting dendritic cell activity, suppressing autoimmune disease symptoms and bone loss. They discovered DCIR binds to glycoproteins on macrophages and osteoclasts, reducing inflammation and immune responses.
Research suggests that obesity triggers inflammation, leading to an increase in myeloid-derived suppressor cells, which break down bone tissue. This can result in gum disease and tooth loss. The study found a significant link between high-fat diets and increased osteoclasts and alveolar bone destruction.
Researchers found that patients with a rare genetic condition may develop chronic inflammatory bone diseases due to an impaired response to interferon gamma. The study suggests that this impairment leads to excessive osteoclast proliferation and increased bone resorption, causing multifocal osteomyelitis.
Researchers have discovered a new type of bone cell called 'osteomorphs' that may reveal new therapeutic approaches for osteoporosis and other skeletal diseases. The cells have a unique genomic profile, suggesting promising targets for therapy.
A recent study has discovered a cell type that governs bone formation and maintenance, shedding light on the mechanisms behind osteoporosis. Researchers found that bone marrow adipogenic lineage precursors (MALPs) play a distinct role in regulating bone remodeling, and targeting these cells could lead to more effective therapies.
A new study among mice shows a diet high in prunes can completely prevent bone loss after spinal cord injury and even restore some of the lost bone. Previous research has also shown positive effects on bone health in post-menopausal women and astronauts exposed to radiation.
A recent study published in Communications Biology reveals that osteoblasts use extracellular vesicles to send signaling molecules to immature osteoclasts, triggering their differentiation into mature cells. This process is crucial for bone repair and regeneration after a fracture.
Researchers at Tokyo University of Science discovered the significance of protein Cpeb4 in the formation of osteoclasts, bone-dissolving cells responsible for osteoporosis and rheumatoid arthritis. The study found that Cpeb4 plays a critical role in osteoclast differentiation, with its relocalization to nuclei influencing cell behavior.
A study published in Nature Communications suggests that age-related changes to spinal cartilaginous tissue can lead to painful nerve growth, causing unexplained low back pain. The research found that a porous structure in the cartilage endplates can invite abnormal nerve growth, making the normal load-bearing work of the spine painful.
Researchers at Osaka University have discovered a previously unknown type of RA-causing cell within arthritic joints that could be a target for new treatments. The newly discovered cells, dubbed 'AtoMs', have properties that make them amenable to therapeutic targeting.
Researchers investigated melatonin's role in preventing bone loss during space flight using cultured goldfish scales. They found that melatonin suppresses bone resorption by stimulating osteoblasts to produce CALCITONIN. This suggests melatonin could serve as a prophylactic drug to prevent bone loss of astronauts.
A new study reveals that damage to mitochondria leads to an increased production of osteoclasts, which break down bone. This process is triggered by stress signaling in cells, leading to greater rates of bone resorption and potentially contributing to osteoporosis.
A University at Buffalo study found that the absence of protein tristetraprolin (TTP) leads to rapid bone loss in mice, with oral bone loss increasing by nearly 20% over nine months. Overexpressing TTP reduced bone turnover by 13%. The research has implications for managing bone health in the elderly.
Researchers used intravital two-photon microscopy to visualize interactions between osteoblasts and osteoclasts in living bone tissue. They found that osteoblasts can inhibit bone resorption by direct contact with osteoclasts, demonstrating an important concept for regulating bone homeostasis.
A new study published in Scientific Reports found that monocyte chemoattractant protein-1 (MCP-1) plays a crucial role in bone loss responses to parathyroid hormone (PTH) in hyperparathyroidism. Elevated MCP-1 levels have been correlated with elevated serum PTH levels, and its presence may serve as a marker for PTH's effects in humans.
Long-term malaria infections can cause chronic inflammation in the bone marrow, leading to increased bone resorption and substantial bone loss. Oral supplementation with alfacalcidol may reverse this side effect, suggesting a potential treatment strategy for improving bone health in malaria-infected individuals.
A new study by Imperial College London suggests that bisphosphonates, a commonly used treatment for osteoporosis, may increase the risk of 'micro-cracks' in bone, leading to reduced mechanical strength. The research found that patients taking the drugs had more microcracks and weaker bones than those who were not on the medication.
Researchers found immediate changes in gene expression of osteoblasts and osteoclasts in medaka fish exposed to microgravity. The study suggests a new area of research in gravitational biology, exploring the molecular mechanisms behind bone structure changes.
A team of Osaka University researchers has developed a method to visualize the function of bone-resorbing cells (osteoclasts) in living mice. This allows for the measurement of bone resorption intensity, enabling early diagnosis and screening of new therapeutic drugs.
Researchers identified microRNA-146a in osteoclast-derived extracellular vesicles, which regulate bone cell function. The study suggests that miR-146a-rich EVs may act as a potential biomarker for osteoclast presence and regulate target cells.
Researchers aboard the International Space Station reared small freshwater fish for 56 days to investigate microgravity's effects on bone density. The study found increased osteoclast activity and reduced bone mineral density in the fish, suggesting a potential link between mitochondria dysfunction and osteoporosis.
A new study led by University of Pennsylvania School of Dental Medicine researchers demonstrates that protein Del-1 can inhibit bone loss associated with periodontitis. The protein curbs the activity of osteoclasts, cells that absorb bone tissue, leading to a mechanistic explanation of how Del-1 can prevent periodontal bone loss.
Researchers found that the Alzheimer's drug donepezil increases bone mass in mice by preventing osteoclasts from being made, reducing the risk of bone fractures. The study suggests that treating Alzheimer's disease with donepezil may also be beneficial for patients with osteoporosis.
Researchers at the University of Toronto's Faculty of Dentistry have identified Adseverin as a key driver behind bone loss associated with periodontitis and other inflammatory diseases. The protein plays a critical role in generating larger osteoclasts, leading to rapid bone loss.
Researchers at Brigham and Women's Hospital have identified certain proteins in osteoclasts that may help destroy cardiovascular calcification by dissolving mineral deposits. The discovery suggests a potential therapeutic avenue for patients with cardiovascular calcification.
Researchers found that chloroquine treatment increased TRAF3 levels in osteoclast precursor cells, limiting osteoclast generation and bone resorption. The study suggests that therapies targeting TRAF3 may help prevent bone loss in individuals with osteoporosis.
Researchers discovered an association between oncometabolite 2-hydroxyglutarate (2-HG) levels and DNA methylation patterns with breast cancer prognosis. Chloroquine treatment was found to limit osteoclast generation, suggesting potential therapeutic applications.
A new study has characterized cells responsible for driving calcium build-up in vessel walls, providing a potential therapeutic target. The researchers found that certain cells can differentiate into osteoclasts, leading to softening of the blood vessels, and that manipulating these cells could lead to a reduction in heart disease risk.
Researchers discovered that steroid drugs can suppress a molecule key to rapid bone loss in rib fractures, reversing bone loss and improving lung function. The study's findings challenge the conventional understanding of steroids as causing bone loss.
A team of researchers led by the University of Pittsburgh School of Medicine has confirmed that a gene from the measles virus plays a key role in the development of Paget's disease of bone. The study found that osteoclasts in affected patients express a viral protein, leading to characteristic bone lesions and increased risk of fracture.
Scientists have discovered a potential therapeutic strategy for reversing rheumatoid arthritis and osteoporosis by manipulating the levels of NF-κB p100, a key inhibitory protein. The study found that increasing NF-κB p100 levels can limit bone destruction and inflammation in both diseases.
Researchers have found that T cells from individuals with X-linked lymphoproliferative disease (XLP) are resistant to cell death triggered by repeated stimulation of a cell surface protein complex, leading to uncontrolled expansion upon infection. Additionally, a molecular regulatory network controlled by the protein SPDEF governs alle...
The Bcl-xL protein prevents bone breakdown by negatively regulating the bone-resorbing activity of osteoclasts. In mice, Bcl-xL promotes osteoclast survival and decreases extracellular matrix production, leading to increased osteoclast-mediated bone resorption.
Scientists discovered that downregulation of IRF-8 gene increases production of osteoclasts responsible for bone breakdown. The study found that IRF-8 suppresses osteoclast activity and inhibits NFATc1 protein function, potentially leading to new therapeutic approaches.
MDC researchers have elucidated a molecular mechanism that regulates the equilibrium between bone formation and bone resorption. They found that two different forms of a gene switch – LAP and LIP – determine this process. The study suggests that an imbalance in the ratio between these two isoforms may play a role in osteoporosis.
Researchers developed a cell-permeable inhibitor of the mouse protein RANK, which blocks osteoclast formation and function, preventing bone destruction. The compound protected against bone loss in two mouse models, suggesting similar drugs may be beneficial for individuals with diseases involving bone destruction.